The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Decrelip     5-(2,5-dimethylphenoxy)-2,2- dimethyl...

Synonyms: Gemhexal, Trialmin, Bolutol, Lipazil, Litarek, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Apo-Gemfibrozil


Psychiatry related information on Apo-Gemfibrozil


High impact information on Apo-Gemfibrozil


Chemical compound and disease context of Apo-Gemfibrozil


Biological context of Apo-Gemfibrozil

  • Six patients with primary familial endogenous hypertriglyceridemia with fasting chylomicronemia (type V lipoprotein phenotype) with concurrent subnormal HDL cholesterol levels (HDL deficiency) were treated initially by diet and once stabilized, were given gemfibrozil (1,200 mg/d) [19].
  • In the bacterial mutagenesis assays, between 100 and 2,500 microgram gemfibrozil/plate failed to induce a significant increase in revertant bacterial colonies [6].
  • Recently, the reduction of the coronary heart disease incidence in the Helsinki Heart Study has implicated favorable modulation of endogenous fibrinolysis by gemfibrozil [20].
  • Most factors related to insulin-resistance syndrome decrease fibrinolytic capacity, whereas a recent study showed that gemfibrozil improves it and thus may attenuate thrombotic events [21].
  • These results implicate protein-DNA interactions at the DRE region in the transcriptional induction of human apoA-I gene expression by gemfibrozil [22].

Anatomical context of Apo-Gemfibrozil


Associations of Apo-Gemfibrozil with other chemical compounds


Gene context of Apo-Gemfibrozil


Analytical, diagnostic and therapeutic context of Apo-Gemfibrozil


  1. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. Frick, M.H., Elo, O., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., Huttunen, J.K., Kaitaniemi, P., Koskinen, P., Manninen, V. N. Engl. J. Med. (1987) [Pubmed]
  2. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. Kesäniemi, Y.A., Grundy, S.M. JAMA (1984) [Pubmed]
  3. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. Robins, S.J., Collins, D., Wittes, J.T., Papademetriou, V., Deedwania, P.C., Schaefer, E.J., McNamara, J.R., Kashyap, M.L., Hershman, J.M., Wexler, L.F., Rubins, H.B. JAMA (2001) [Pubmed]
  4. Hyperlipidemia and pancreatitis during pregnancy in two sisters with a mutation in the lipoprotein lipase gene. Keilson, L.M., Vary, C.P., Sprecher, D.L., Renfrew, R. Ann. Intern. Med. (1996) [Pubmed]
  5. Combination drug therapy for familial combined hyperlipidemia. East, C., Bilheimer, D.W., Grundy, S.M. Ann. Intern. Med. (1988) [Pubmed]
  6. Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. Fitzgerald, J.E., Sanyer, J.L., Schardein, J.L., Lake, R.S., McGuire, E.J., de la Iglesia, F.A. J. Natl. Cancer Inst. (1981) [Pubmed]
  7. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Rubins, H.B., Robins, S.J., Collins, D., Nelson, D.B., Elam, M.B., Schaefer, E.J., Faas, F.H., Anderson, J.W. Arch. Intern. Med. (2002) [Pubmed]
  8. Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. Knight, R.J., Vathsala, A., Schoenberg, L., Camel, S., Weinberg, R.B., Goldstein, R.A., Lewis, R.M., van Buren, C.T., Kahan, B.D. Transplantation (1992) [Pubmed]
  9. Alcohol and coronary heart disease: the roles of HDL-cholesterol and smoking. Mänttäri, M., Tenkanen, L., Alikoski, T., Manninen, V. J. Intern. Med. (1997) [Pubmed]
  10. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Tornio, A., Neuvonen, P.J., Backman, J.T. Eur. J. Clin. Pharmacol. (2006) [Pubmed]
  11. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., Faas, F.H., Linares, E., Schaefer, E.J., Schectman, G., Wilt, T.J., Wittes, J. N. Engl. J. Med. (1999) [Pubmed]
  12. Statin-associated myopathy. Thompson, P.D., Clarkson, P., Karas, R.H. JAMA (2003) [Pubmed]
  13. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. Vega, G.L., Grundy, S.M. JAMA (1990) [Pubmed]
  14. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. Pierce, L.R., Wysowski, D.K., Gross, T.P. JAMA (1990) [Pubmed]
  15. Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages. Rudin, D.E., Gao, P.X., Cao, C.X., Neu, H.C., Silverstein, S.C. J. Exp. Med. (1992) [Pubmed]
  16. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Manninen, V., Tenkanen, L., Koskinen, P., Huttunen, J.K., Mänttäri, M., Heinonen, O.P., Frick, M.H. Circulation (1992) [Pubmed]
  17. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. Lovett-Racke, A.E., Hussain, R.Z., Northrop, S., Choy, J., Rocchini, A., Matthes, L., Chavis, J.A., Diab, A., Drew, P.D., Racke, M.K. J. Immunol. (2004) [Pubmed]
  18. Fibrates, dyslipoproteinaemia and cardiovascular disease. Watts, G.F., Dimmitt, S.B. Curr. Opin. Lipidol. (1999) [Pubmed]
  19. Mechanism of action of gemfibrozil on lipoprotein metabolism. Saku, K., Gartside, P.S., Hynd, B.A., Kashyap, M.L. J. Clin. Invest. (1985) [Pubmed]
  20. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors. Nordt, T.K., Kornas, K., Peter, K., Fujii, S., Sobel, B.E., Kübler, W., Bode, C. Circulation (1997) [Pubmed]
  21. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Tenkanen, L., Mänttäri, M., Manninen, V. Circulation (1995) [Pubmed]
  22. Protein-DNA interactions at a drug-responsive element of the human apolipoprotein A-I gene. Zhang, X., Chen, Z.Q., Wang, Z., Mohan, W., Tam, S.P. J. Biol. Chem. (1996) [Pubmed]
  23. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. Gonzalez, F.J., Peters, J.M., Cattley, R.C. J. Natl. Cancer Inst. (1998) [Pubmed]
  24. Dyslipidemia and atherosclerosis. A forecast of pharmaceutical approaches. Gotto, A.M. Circulation (1993) [Pubmed]
  25. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1. Fujii, S., Sobel, B.E. Circulation (1992) [Pubmed]
  26. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. Pahan, K., Jana, M., Liu, X., Taylor, B.S., Wood, C., Fischer, S.M. J. Biol. Chem. (2002) [Pubmed]
  27. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Syvänne, M., Nieminen, M.S., Frick, M.H., Kauma, H., Majahalme, S., Virtanen, V., Kesäniemi, Y.A., Pasternack, A., Ehnholm, C., Taskinen, M.R. Circulation (1998) [Pubmed]
  28. Bezafibrate as differentiating factor of human myeloid leukemia cells. Scatena, R., Nocca, G., Sole, P.D., Rumi, C., Puggioni, P., Remiddi, F., Bottoni, P., Ficarra, S., Giardina, B. Cell Death Differ. (1999) [Pubmed]
  29. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Garg, A., Grundy, S.M. Diabetes (1989) [Pubmed]
  30. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Wiklund, O., Angelin, B., Bergman, M., Berglund, L., Bondjers, G., Carlsson, A., Lindén, T., Miettinen, T., Odman, B., Olofsson, S.O. Am. J. Med. (1993) [Pubmed]
  31. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J. Diabetologia (2003) [Pubmed]
  32. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. Xu, J., Chavis, J.A., Racke, M.K., Drew, P.D. J. Neuroimmunol. (2006) [Pubmed]
  33. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Kahri, J., Vuorinen-Markkola, H., Tilly-Kiesi, M., Lahdenperä, S., Taskinen, M.R. Atherosclerosis (1993) [Pubmed]
  34. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. Yang, C.Y., Gu, Z.W., Xie, Y.H., Valentinova, N.V., Yang, M., Yeshurun, D., Quion, J.A., Gotto, A.M. Atherosclerosis (1996) [Pubmed]
  35. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Wang, J.S., Neuvonen, M., Wen, X., Backman, J.T., Neuvonen, P.J. Drug Metab. Dispos. (2002) [Pubmed]
  36. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients. Kahri, J., Sane, T., van Tol, A., Taskinen, M.R. J. Intern. Med. (1995) [Pubmed]
  37. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. Leaf, D.A., Connor, W.E., Illingworth, D.R., Bacon, S.P., Sexton, G. JAMA (1989) [Pubmed]
  38. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Frick, M.H., Syvänne, M., Nieminen, M.S., Kauma, H., Majahalme, S., Virtanen, V., Kesäniemi, Y.A., Pasternack, A., Taskinen, M.R. Circulation (1997) [Pubmed]
WikiGenes - Universities